Startup Pepper Bio Touts ‘Transomics’ as Key Strategy in its Drug Discovery Efforts

Reposted from Neil Versel, Editor at GenomeWeb CHICAGO – While multiomics seems to be a top biotech buzzword these days, drug discovery and bioinformatics startup Pepper Bio is trying to make a name for itself in the field of transomics. To that end, the Boston-based startup is leveraging support from Merck and other entities as part of an accelerator program to try and hone its strategy for applications such as…

Comments Off on Startup Pepper Bio Touts ‘Transomics’ as Key Strategy in its Drug Discovery Efforts

Ex-Phio VP, Simon Fricker, Joins Pepper Bio As Chief Development Officer

By Jon Hu, CEO and Cofounder of Pepper Bio  Pepper Bio, the world’s first transomics drug discovery company, announced the addition of Simon Fricker, Ph.D., as chief development officer. Previously, Dr. Fricker served three years as vice president of research and development at Phio Pharmaceuticals, a publicly-traded clinical-stage biotechnology company, and eight years as a distinguished scientific fellow at Genzyme/Sanofi. In his new role at Pepper, Dr. Fricker will support the…

Comments Off on Ex-Phio VP, Simon Fricker, Joins Pepper Bio As Chief Development Officer

Pharma’s Blind Spot: Successfully Using AI To Drive Drug Development

Jon Hu Forbes Councils Member Artificial intelligence (AI) has penetrated nearly every industry, but the pharmaceutical industry could arguably benefit from AI the most. According to the results of a study performed by Insider Intelligence, AI has the potential to curb drug discovery costs for pharma companies by nearly 70%. It can do this by making accurate, more nuanced predictions about a disease or drug. However, if the data feeding into…

Comments Off on Pharma’s Blind Spot: Successfully Using AI To Drive Drug Development

The Root Cause Of Pharma’s Drug Development Problem

Jon Hu Forbes Councils Member Everyone likes to point fingers at big pharma. They’ll point to how much money it takes to develop a single drug (up to $2.8 billion on average)—or point to how a drug caused severe, long-term side effects that result in it coming off the market—ultimately throwing that money down the drain. But ironically, they’re missing the point. The problem isn’t the cost; the cost is an effect…

Comments Off on The Root Cause Of Pharma’s Drug Development Problem

Stanford Lab Aligns With Pepper Bio To Target Tough Cancers

The drug discovery firm will work with the Dean Felsher laboratory, using the company's transomics platform to discover therapies for untreatable cancers. Researchers at Stanford University's Dean Felsher laboratory have announced plans to collaborate with drug discovery company Pepper Bio in an effort to identify therapeutic targets for untreatable lymphatic and liver cancers. With the help of Pepper Bio's platform on phosphoproteomics, the collaborators reportedly aim to identify and validate…

Comments Off on Stanford Lab Aligns With Pepper Bio To Target Tough Cancers

Pepper Bio Partners with Stanford’s Felsher Lab to Identify Therapy Targets for Untreatable, MYC Addicted Lymphatic and Liver Cancers

Leveraging Pepper Bio’s transomics platform, Dean Felsher’s research team will translate academic findings for the development of more efficacious therapies for lymphoma and hepatocellular carcinoma Today, Pepper Bio, the world’s first transomics drug discovery company, announced a collaboration with the Dean Felsher Laboratory at Stanford University. Leveraging Pepper Bio’s unique platform on phosphoproteomics, the two teams aim to identify and validate novel targets for hepatocellular carcinoma and lymphoma within the year. Read on…

Comments Off on Pepper Bio Partners with Stanford’s Felsher Lab to Identify Therapy Targets for Untreatable, MYC Addicted Lymphatic and Liver Cancers